Clinical Trials on Inherited Epidermolysis Bullosa in Russian Federation

Total 84 results

National Medical Research Center for Children's...

Active, not recruiting

The State of Sexual Development in Children With Inherited Epidermolysis Bullosa

Epidermolysis Bullosa | Hormone Disturbance | Epidermolysis Bullosa Dystrophica | Epidermolysis Bullosa Simplex | Dermatologic Disease | Epidermolysis Bullosa, Junctional | Puberty Disorders | Kindler Syndrome

Russian Federation
National Medical Research Center for Children's...

Recruiting

Vitamin D Status and Bone Metabolism Status in Children With Congenital Epidermolysis Bullosa

Vitamin D Deficiency | Osteoporosis | Osteopenia | Phosphorus and Calcium Disorders | Bullosa Epidermolysis

Russian Federation
Sechenov University
Pirogov Russian National Research Medical University

Recruiting

Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population

Bullous Pemphigoid | Stevens-Johnson Syndrome | Toxic Epidermal Necrolyses | Pemphigus

Russian Federation
Amryt Research Limited

Completed

Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa (EASE)

Epidermolysis Bullosa

United States, Spain, Israel, Australia, France, Denmark, Switzerland, Italy, Hong Kong, Argentina, Austria, Brazil, Chile, Colombia, Czechia, Georgia, Germany, Greece, Hungary, Ireland, Romania, Russian Federation, Serbia, Singapore, U... and more
The League of Clinical Research, Russia

Completed

Health Related Quality of Life of Youth and Young Adults With Haemophilia A (RELOQ)

Hemophilia A

Russian Federation
Federal Research Institute of Pediatric Hematology...

Completed

Romiplostim Treatment for Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome.

Wiskott-Aldrich Syndrome

Russian Federation
Federal Research Institute of Pediatric Hematology...

Unknown

A Trial of Plerixafor/G-CSF as Additional Agents for Conditioning Before TCR Alpha/Beta Depleted HSCT in WAS Patients

Hematopoietic Stem Cell Transplantation | Wiskott-Aldrich Syndrome | Graft Failure

Russian Federation
Federal Research Institute of Pediatric Hematology...

Recruiting

Efficacy and Safety of Romiplostim Versus Eltrombopag in the Treatment of Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome

Wiskott-Aldrich Syndrome

Russian Federation
Recoly N.V.

Completed

Study of the Efficacy of Human Recombinant Factor VIII (Kogenate FS) Reconstituted in Pegylated Liposomes.

Haemophilia A

Russian Federation
Octapharma

Completed

Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia A

Severe Hemophilia A

Russian Federation, Ukraine
Ascension Healthcare Development Limited

Recruiting

A Pharmacokinetic and Clotting Activity Study of FVIII-PEGLip

Hemophilia A With Inhibitor

Russian Federation
Baxalta now part of Shire

Completed

Pharmacokinetic Study of ADVATE 3000 IU in Previously Treated Patients With Severe Hemophilia A

Hemophilia A

Bulgaria, Russian Federation
Bayer

Completed

Russian Kogenate Pediatric Study

Hemophilia A

Russian Federation
Bio Products Laboratory

Completed

An Open-study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Subjects Undergoing Surgery

Haemophilia B

Poland, Romania, Russian Federation
CSL Behring
Parexel

Completed

Study of a pd VWF/FVIII Concentrate, Biostate®, in Subjects With Von Willebrand Disease

Von Willebrand Disease

Bulgaria, Poland, Russian Federation, Ukraine
CSL Behring

Completed

Extension Study of Biostate in Subjects With Von Willebrand Disease

Von Willebrand Disease

Bulgaria, Germany, Poland, Russian Federation, Ukraine
Catalyst Biosciences

Completed

Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia

Hemophilia A | Hemophilia B | Hemophilia A With Inhibitor | Hemophilia B With Inhibitor | Hemophilia A Without Inhibitor | Hemophilia B Without Inhibitor

Bulgaria, Russian Federation
CSL Behring

Terminated

Study of Biostate for Treatment of Children With Hemophilia A Complicated by Antibody Development

Hemophilia A

Russian Federation, Germany, Italy, Austria, Greece
Octapharma

Completed

Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A

Severe Hemophilia A

Bulgaria, Poland, Hungary, Romania, Russian Federation
Biocad

Recruiting

A Trial of the Safety and Efficacy of Single-Dose Administration of ANB-010 in Subjects With Hemophilia A (EDELWEISS)

Hemophilia A

Russian Federation
Biocad

Recruiting

Study of the Safety, Pharmacodynamics and Efficacy of ANB-002 in Patients With Hemophilia B (SAFRAN)

Hemophilia B

Russian Federation
Catalyst Biosciences

Completed

Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B

Hemophilia A With Inhibitor | Hemophilia B With Inhibitor

Armenia, Georgia, South Africa, Poland, Russian Federation
Takeda

Completed

A Study of Standard and Individualized Prophylactic Treatment With Advate in Men and Boys With Severe Hemophilia A (HAPKIDO)

Hemophilia A

Russian Federation
Laboratoire français de Fractionnement et de Biotechnologies
LFB USA, Inc.

Completed

LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures (PerSept3)

Hemophilia

United States, Ukraine, Mexico, Russian Federation, South Africa, Spain
Baxalta now part of Shire

Completed

BAX 326 Pediatric Study

Hemophilia B

Russian Federation, Ukraine, India, Poland, Romania, United Kingdom
Genzyme, a Sanofi Company

Completed

An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B

Hemophilia A | Hemophilia B

Bulgaria, United States, United Kingdom, Russian Federation, Switzerland
CSL Behring
Parexel

Completed

Study of a pd vWF/FVIII, Biostate®, in Subjects With Haemophilia A

Hemophilia A

Bulgaria, Poland, Russian Federation, Macedonia, The Former Yugoslav Republic of
Octapharma

Active, not recruiting

Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease VWD) Patients <6 Years of Age

Von Willebrand Disease

United States, Moldova, Republic of, Czechia, Germany, North Macedonia, Russian Federation, Ukraine
Sanofi

Completed

A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients

Hemophilia A | Hemophilia B

Bulgaria, Switzerland, United Kingdom, United States, Russian Federation
Octapharma

Completed

Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWD

Von Willebrand Diseases

Lebanon, Croatia, United States, Belarus, Bulgaria, Hungary, Russian Federation, Ukraine
Baxalta now part of Shire

Completed

BAX 326 Surgery Study in Hemophilia B Patients

Hemophilia B

Colombia, Bulgaria, Chile, Poland, Romania, Argentina, Czechia, Russian Federation, Ukraine, United Kingdom
Bayer

Completed

EFFEKT - Efficacy and Safety of Long-term Treatment With KOGENATE Bayer/FS

Hemophilia A

Croatia, Germany, Saudi Arabia, Kazakhstan, Romania, Russian Federation, Slovenia, Bahrain, United Arab Emirates, Bosnia and Herzegovina, Israel, Kuwait, Libyan Arab Jamahiriya, Morocco, Oman, Qatar, Tunisia
Octapharma

Completed

Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment

Von Willebrand Diseases

Lebanon, Croatia, United States, Hungary, Russian Federation, Ukraine, Belarus, Bulgaria
CSL Behring

Terminated

Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors

Hemophilia A With Inhibitors | Hemophilia B With Inhibitors

Georgia, Italy, Malaysia, Russian Federation, South Africa, Spain, Thailand, Ukraine, United Kingdom
Octapharma

Completed

Efficacy and Safety Study of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery

Congenital Fibrinogen Deficiency

United States, Bulgaria, India, Iran, Islamic Republic of, Lebanon, Russian Federation, Saudi Arabia, Turkey, United Kingdom
Baxalta now part of Shire

Completed

Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen

Hemophilia A | Hemophilia B

Japan, Russian Federation, Spain, United States, Poland, Romania, Serbia, Taiwan, Ukraine
Baxalta now part of Shire

Completed

IMMUNINE Pre-Treatment Study

Hemophilia B

Colombia, Bulgaria, Chile, Poland, Romania, Argentina, Brazil, Czechia, Russian Federation, Ukraine
CSL Behring

Completed

A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B

Hemophilia B

Germany, Australia, Italy, Israel, Czech Republic, Spain, France, Canada, Austria, Russian Federation
Baxalta now part of Shire
Baxter Innovations GmbH

Terminated

Early Prophylaxis Immunologic Challenge (EPIC) Study (EPIC)

Hemophilia A

Poland, United States, Bulgaria, Serbia, Canada, Russian Federation, Germany, Netherlands, Lithuania, Czechia, Austria, Spain
Pfizer

Completed

Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia B

Hemophilia B

United States, Spain, Croatia, Serbia, Russian Federation, Canada, Hungary, Italy, Romania
Baxalta now part of Shire

Completed

Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor

Hemophilia A | Hemophilia B | Hemophilia A or B With Inhibitors

Poland, United States, Bulgaria, Romania, Japan, Russian Federation, New Zealand, Croatia, Ukraine, Brazil
Baxalta now part of Shire

Completed

Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B Patients

Hemophilia B

Poland, United Kingdom, Spain, Bulgaria, Romania, Japan, Russian Federation, Brazil, Chile, Sweden, Colombia, Ukraine, Argentina, Czechia
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Terminated

BAX 802 in CHA With Inhibitors (CHAWI)

Hemophilia A

Netherlands, Spain, Italy, Turkey, Bulgaria, United States, Canada, Germany, Norway, Poland, Russian Federation, South Africa
rEVO Biologics
Laboratoire français de Fractionnement et de Biotechnologies

Completed

Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors

Hemophilia A With Inhibitors | Hemophilia B With Inhibitors

United States, Bulgaria, Poland, Russian Federation, Belarus, Georgia, Israel, Romania, Ukraine, United Kingdom
Baxalta now part of Shire

Completed

BAX 826 Dose-Escalation Safety Study

Hemophilia A

Spain, Bulgaria, Germany, United Kingdom, Italy, Poland, Russian Federation, Netherlands, Hungary
Catalyst Biosciences

Terminated

Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders

Factor VII Deficiency | Hemophilia A With Inhibitor | Glanzmann Thrombasthenia

United States, India, Italy, Russian Federation, Ukraine
Baxalta now part of Shire

Completed

Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A

Hemophilia A

United States, Poland, Slovenia, Greece, Russian Federation, Hungary, Italy, United Kingdom, Czechia, Austria
Grifols Therapeutics LLC
Grifols Biologicals, LLC

Terminated

Alphanate in Immune Tolerance Induction Therapy

Hemophilia A, Congenital

United States, Spain, Italy, India, Canada, Russian Federation
Baxalta now part of Shire

Completed

Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures

Hemophilia A

United States, Spain, Netherlands, United Kingdom, Bulgaria, Lithuania, Russian Federation, Switzerland, Ukraine
CSL Behring

Completed

A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B

Hemophilia B

United States, Japan, Israel, Austria, Bulgaria, France, Germany, Italy, Russian Federation, Spain

Clinical Trials on Inherited Epidermolysis Bullosa in Russian Federation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Singapore

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations